Liu Lei Amends China Jo-Jo Drugstores 13D Filing

TL;DR

Liu Lei updated their 13D filing for China Jo-Jo Drugstores. Watch for potential changes.

AI Summary

Lei Liu filed an amendment (No. 2) to Schedule 13D on September 3, 2024, for China Jo-Jo Drugstores, Inc. This filing relates to the ordinary shares of the company. The filing indicates a change in the reporting person's holdings or intentions regarding the company's securities.

Why It Matters

Amendments to Schedule 13D filings signal potential shifts in significant shareholder positions or strategies, which can impact stock price and corporate governance.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant shareholder activity, which can lead to volatility or strategic shifts in the company.

Key Players & Entities

• Lei Liu (person) — Reporting Person
• China Jo-Jo Drugstores, Inc. (company) — Subject Company
• Ordinary Shares (security) — Class of Securities

FAQ

Key Financial Figures

• $0.24 — of Issuer) Ordinary Shares, par value $0.24 per share (Title of Class of Securitie
• $4,693,700 — he Purchased Shares was approximately US$4,693,700. ITEM 4. PURPOSE OF TRANSACTION. Ite
• $1.87 — he Purchase Agreements, at a price of US$1.87 per share, upon notice of such Investor

Filing Documents

• ea0212704-13da2liu_china.htm (SC 13D/A) — 32KB
• 0001213900-24-074760.txt ( ) — 34KB

SOURCE AND AMOUNT OF FUNDS OR OTHER

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

of the Schedule 13D

Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following information: The Purchased Shares (as defined below) are purchased with the Reporting Person’s personal funds. The aggregate purchase price of the Purchased Shares was approximately US$4,693,700.

PURPOSE OF TRANSACTION

ITEM 4. PURPOSE OF TRANSACTION.

of the Schedule 13D

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following information: On June 11, 2024, the Company entered into those certain Share Purchase Agreements (the “Purchase Agreements”), dated as of June 11, 2024, with the purchasers signatory thereto (the “Investors”), and solely for the limited and express purpose of Section 2(b) thereof, the Reporting Person, a form of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Under Section 2(b) of the Purchase Agreements, the Reporting Person has voluntarily agreed to purchase, in his individual capacity as a majority shareholder of the Company, from certain Investors all or part of the Ordinary Shares purchased by such Investors under the Purchase Agreements, within six month of the date of the Purchase Agreements, at a price of US$1.87 per share, upon notice of such Investors in accordance with the notices provision set forth in Section 6(b)(iv) of the Purchase Agreements. As of the date of this Amendment No. 2, 13 Investors have provided notices to the Reporting Person exercising their rights under Section 2(b) of the Purchase Agreements in respect of a total of 2,510,000 Ordinary Shares (the “Purchased Shares”). The Reporting Person acquired the Purchased Shares at a price of US$1.87 per share on or about August 30, 2024. 3

INTEREST IN SECURITIES OF THE ISSUER

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

of the Schedule 13D

Item 5 of the Schedule 13D is hereby amended and restated as follows: (a) See rows (11) and (13) of the cover pages to this Amendment No. 2 for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by the Reporting Person. The percentage used in this Amendment No. 2 is calculated based upon an aggregate of 6,654,077 Ordinary Shares issued and outstanding as of the date hereof. (b) See rows (7) through (10) of the cover pages to this Amendment No. 2 for the number of Ordinary Shares as to which the Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. (c) Except as described in

, the Reporting Person has not effected any transaction in the Ordinary Shares within the past sixty days

Item 4, the Reporting Person has not effected any transaction in the Ordinary Shares within the past sixty days. (d) No person other than Mr. Lei Liu is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, such Ordinary Shares. (e) Not applicable.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. Other than as disclosed in Items 3, 4 and 5, to the knowledge of the Reporting Person, there are no contracts, arrangements, understandings or relationships with respect to securities of the Issuer enumerated in Item 6 of Schedule 13D.

MATERIALS TO BE FILED AS EXHIBITS

ITEM 7. MATERIALS TO BE FILED AS EXHIBITS. Exhibit 99.1 Form of Purchase Agreement (Incorporated by reference to Exhibit 10.1 to the Form 6-K furnished by China Jo-Jo Drugstores, Inc. on June 11, 2024). 4

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: September 3, 2024 /s/ Lei Liu Lei Liu 5

View Full Filing

View this SC 13D/A filing on SEC EDGAR